With age comes a greater comorbidity burden, noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University College of Pharmacy who practices at Northwestern Medicine's Infectious Disease Center in Chicago.
With age comes a greater comorbidity burden, and this process in people living with HIV might necessitate earlier screenings compared with people not living with HIV, noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University College of Pharmacy who practices at Northwestern Medicine's Infectious Disease Center in Chicago.
Transcript
What are the top primary care issues among individuals living with HIV as they age?
I really see a lot of comorbidities and a lot of primary care. So a lot of hyperlipidemia management, diabetes management; hypertension is a very big prevalence. And as patients age, they usually have more comorbidities and more things that they are looking to treat. And so we know this process is also accelerated in patients living with HIV and that they might need screenings typically earlier than a patient not living with HIV.
In this population, I really love to mitigate those drug-drug interactions with all the comedications. That's a big role for pharmacists, as well as family planning over the course of lives and just making sure that patients’ wishes for family planning are known as well, because that can impact which medications we might be using to not only treat the HIV but to treat comorbid conditions.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More